AMRN
Price
$15.38
Change
-$0.11 (-0.71%)
Updated
Jul 25 closing price
Capitalization
357.53M
3 days until earnings call
GRFS
Price
$10.10
Change
+$0.16 (+1.61%)
Updated
Jul 25 closing price
Capitalization
5.48B
2 days until earnings call
Interact to see
Advertisement

AMRN vs GRFS

Header iconAMRN vs GRFS Comparison
Open Charts AMRN vs GRFSBanner chart's image
Amarin
Price$15.38
Change-$0.11 (-0.71%)
Volume$77.78K
Capitalization357.53M
Grifols SA
Price$10.10
Change+$0.16 (+1.61%)
Volume$784.24K
Capitalization5.48B
AMRN vs GRFS Comparison Chart in %
Loading...
AMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMRN vs. GRFS commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a Hold and GRFS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (AMRN: $15.39 vs. GRFS: $10.10)
Brand notoriety: AMRN: Notable vs. GRFS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMRN: 62% vs. GRFS: 90%
Market capitalization -- AMRN: $357.53M vs. GRFS: $5.48B
AMRN [@Pharmaceuticals: Major] is valued at $357.53M. GRFS’s [@Pharmaceuticals: Major] market capitalization is $5.48B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRN’s FA Score shows that 0 FA rating(s) are green whileGRFS’s FA Score has 1 green FA rating(s).

  • AMRN’s FA Score: 0 green, 5 red.
  • GRFS’s FA Score: 1 green, 4 red.
According to our system of comparison, GRFS is a better buy in the long-term than AMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRN’s TA Score shows that 4 TA indicator(s) are bullish while GRFS’s TA Score has 5 bullish TA indicator(s).

  • AMRN’s TA Score: 4 bullish, 5 bearish.
  • GRFS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, GRFS is a better buy in the short-term than AMRN.

Price Growth

AMRN (@Pharmaceuticals: Major) experienced а -2.75% price change this week, while GRFS (@Pharmaceuticals: Major) price change was +1.61% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.43%. For the same industry, the average monthly price growth was +7.37%, and the average quarterly price growth was +13.00%.

Reported Earning Dates

AMRN is expected to report earnings on Jul 30, 2025.

GRFS is expected to report earnings on Jul 29, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+3.43% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GRFS($5.48B) has a higher market cap than AMRN($358M). GRFS (68.68) and AMRN (67.11) have similar P/E ratio . AMRN YTD gains are higher at: 58.608 vs. GRFS (35.753). GRFS has higher annual earnings (EBITDA): 640M vs. AMRN (-50.7M). GRFS has more cash in the bank: 544M vs. AMRN (321M). AMRN has less debt than GRFS: AMRN (8.74M) vs GRFS (11.1B). GRFS has higher revenues than AMRN: GRFS (6.54B) vs AMRN (307M).
AMRNGRFSAMRN / GRFS
Capitalization358M5.48B7%
EBITDA-50.7M640M-8%
Gain YTD58.60835.753164%
P/E Ratio67.1168.6898%
Revenue307M6.54B5%
Total Cash321M544M59%
Total Debt8.74M11.1B0%
FUNDAMENTALS RATINGS
AMRN vs GRFS: Fundamental Ratings
AMRN
GRFS
OUTLOOK RATING
1..100
7830
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
6
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9387
PRICE GROWTH RATING
1..100
4639
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GRFS's Valuation (6) in the Pharmaceuticals Major industry is significantly better than the same rating for AMRN (87) in the Pharmaceuticals Other industry. This means that GRFS’s stock grew significantly faster than AMRN’s over the last 12 months.

GRFS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that GRFS’s stock grew similarly to AMRN’s over the last 12 months.

GRFS's SMR Rating (87) in the Pharmaceuticals Major industry is in the same range as AMRN (93) in the Pharmaceuticals Other industry. This means that GRFS’s stock grew similarly to AMRN’s over the last 12 months.

GRFS's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as AMRN (46) in the Pharmaceuticals Other industry. This means that GRFS’s stock grew similarly to AMRN’s over the last 12 months.

GRFS's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that GRFS’s stock grew similarly to AMRN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRNGRFS
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
72%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
69%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
69%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 19 days ago
73%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 10 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
67%
Aroon
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
AMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UMICF18.03N/A
N/A
Umicore SA
PSTVY14.66N/A
N/A
Postal Svgs Bk of China Ltd.
YLWDF8.23N/A
N/A
Yellow Pages Ltd.
PEYUF14.11-0.16
-1.12%
Peyto Exploration & Development Corp
CPNFF0.11-0.01
-7.45%
Euro Sun Mining Inc.

AMRN and

Correlation & Price change

A.I.dvisor tells us that AMRN and OGN have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AMRN and OGN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRN
1D Price
Change %
AMRN100%
-0.74%
OGN - AMRN
28%
Poorly correlated
+1.39%
PFE - AMRN
27%
Poorly correlated
-0.52%
BIIB - AMRN
21%
Poorly correlated
-0.81%
SCLX - AMRN
20%
Poorly correlated
+11.57%
GRFS - AMRN
20%
Poorly correlated
+1.61%
More

GRFS and

Correlation & Price change

A.I.dvisor tells us that GRFS and BIIB have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GRFS and BIIB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
+1.61%
BIIB - GRFS
28%
Poorly correlated
-0.81%
GILD - GRFS
28%
Poorly correlated
+2.65%
GIFOF - GRFS
26%
Poorly correlated
N/A
SNY - GRFS
24%
Poorly correlated
+0.48%
AMRN - GRFS
20%
Poorly correlated
-0.74%
More